EUVIMEDEUVIMED entdecken
Crossref

Polyamine depletion limits progression of acute leukaemia

Weiman Gao, Mawar Karsa, Lin Xiao, Dayna Spurling, Ayu Karsa, Emma Ronca, Angelika Bongers, Xinyi Guo, Chelsea Mayoh, Mujahid Azfar, Steven H L Verhelst, Katsunori Tanaka und 8 weitere

International Journal of Cancer · 15.06.2025 · 156 (12) · 2360-2376

DOI: 10.1002/ijc.35362 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Cancer, online erschienen am 22.02.2025. Verfasst von Weiman Gao und 19 weiteren Autor:innen. Beteiligte Einrichtung: Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Polyamines, Eflornithine, Leukemia, Leukemia, Myeloid, Acute. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 60 Literaturangaben. Gefördert von: Cancer Australia and the Kids' Cancer Project, FWO Research Grants, C1 KU Leuven Research Grant InterAction.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cancer cells are addicted to polyamines, polycations essential for cellular function. While dual targeting of cellular polyamine biosynthesis and polyamine uptake is under clinical investigation in solid cancers, preclinical and clinical studies into its potential in haematological malignancies are lacking. Here we investigated the preclinical efficacy of polyamine depletion in acute leukaemia. The polyamine biosynthesis inhibitor difluoromethylornithine (DFMO) inhibited growth of a molecularly diverse panel of acute leukaemia cell lines, while non‐malignant cells were unaffected. Responsiveness to DFMO was linked to decreased levels of its molecular target, the rate‐limiting polyamine biosynthesis enzyme ODC1, and of the polyamine transporters ATP13A2 and ATP13A3. DFMO increased polyamine uptake and upregulated expression of polyamine transporters in acute leukaemia cells, a compensatory effect abolished by treatment with the polyamine transport inhibitor AMXT 1501. This drug, currently in a phase 1 clinical trial in solid tumours in combination with DFMO, potentiated the inhibitory effects of DFMO, and their combination synergistically inhibited the growth of acute leukaemia cell lines by inducing apoptosis. DFMO and AMXT 1501 limited disease progression in highly aggressive xenograft models of infant KMT2A ‐rearranged leukaemia, even when treatment was initiated at high disease burden. Increased expression of c‐MYC was associated with enhanced sensitivity to the combination of DFMO and AMXT 1501, suggesting this oncoprotein as a potential predictive marker of response to the drug combination. In conclusion, targeting polyamine biosynthesis and polyamine uptake limits disease progression in models of acute leukaemia, supporting further preclinical and clinical investigation into this approach for acute leukaemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PolyaminesEflornithineLeukemiaLeukemia, Myeloid, AcuteHumansAnimalsMiceXenograft Model Antitumor AssaysCell Line, TumorApoptosisDisease ProgressionCell ProliferationMyeloid-Lymphoid Leukemia Protein

Stichwörter der Autor:innen

DFMOacute leukaemiapolyamine depletionpolyamine transportpolyamines

Substanzen

PolyaminesEflornithineMyeloid-Lymphoid Leukemia Protein

Autor:innen und Institutionen

  • Children's Cancer Institute, Lowy Cancer Research Centre, UNSW Sydney, Sydney, New South Wales, Australia.
  • School of Clinical Medicine, UNSW Medicine & Health, UNSW Centre for Childhood Cancer research, UNSW Sydney, Sydney, New South Wales, Australia.
  • Laboratory of Cellular Transport Systems, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Laboratory of Chemical Biology, Department of Cellular and Molecular Medicine, KU Leuven, Leuven, Belgium.
  • Department of Chemical Science and Engineering, School of Materials and Chemical Technology, Tokyo Institute of Technology, Tokyo, Japan.
  • Biofunctional Synthetic Chemistry Laboratory, RIKEN Cluster for Pioneering Research, Saitama, Japan.

ORCID-Profile: Rishi S Kotecha

Förderung

  • Cancer Australia and the Kids' Cancer Project
  • FWO Research Grants
  • C1 KU Leuven Research Grant InterAction
  • Australian National Health and Medical Research Council
  • Medical Research Council

Zitieren

APA

Gao, W., Karsa, M., Xiao, L., Spurling, D., Karsa, A., Ronca, E., Bongers, A., Guo, X., Mayoh, C., Azfar, M., Verhelst, S. H. L., Tanaka, K., Cheung, L. C., Kotecha, R. S., Lock, R. B., Burns, M. R., Vangheluwe, P., Norris, M. D., Haber, M., & Somers, K. (2025). Polyamine depletion limits progression of acute leukaemia. International Journal of Cancer, 156(12), 2360-2376. https://doi.org/10.1002/ijc.35362

Vancouver

Gao W, Karsa M, Xiao L, Spurling D, Karsa A, Ronca E, et al. Polyamine depletion limits progression of acute leukaemia. International Journal of Cancer. 2025;156(12):2360-2376. doi:10.1002/ijc.35362

BibTeX
@article{Gao2025,
  author = {Gao, Weiman and Karsa, Mawar and Xiao, Lin and Spurling, Dayna and Karsa, Ayu and Ronca, Emma and Bongers, Angelika and Guo, Xinyi and Mayoh, Chelsea and Azfar, Mujahid and Verhelst, Steven H L and Tanaka, Katsunori and Cheung, Laurence C and Kotecha, Rishi S and Lock, Richard B and Burns, Mark R and Vangheluwe, Peter and Norris, Murray D and Haber, Michelle and Somers, Klaartje},
  title = {Polyamine depletion limits progression of acute leukaemia},
  journal = {International Journal of Cancer},
  year = {2025},
  volume = {156},
  number = {12},
  pages = {2360--2376},
  doi = {10.1002/ijc.35362}
}
Kostenlos starten →